Pharmaceutical Stocks To Watch Now - November 6th

Key Points

• Seven pharmaceutical stocks flagged for investor attention based on recent dollar trading volume: Eli Lilly, Pfizer, Johnson & Johnson, AbbVie, Merck, Rhythm Pharmaceuticals, and Regeneron.
• In Friday trading, most of the named stocks rose: Eli Lilly, J&J, AbbVie, Rhythm, and Regeneron gained, while Pfizer and Merck edged lower.
• The companies span major drug and healthcare businesses, with exposure to areas including diabetes and obesity, vaccines, oncology, immunology, and rare diseases; the article notes that pharma shares can be affected by trial results, regulatory decisions, patent expirations, and competition.

Eli Lilly and Company, Pfizer, Johnson & Johnson, AbbVie, Merck & Co., Inc., Rhythm Pharmaceuticals, and Regeneron Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, or sell medicines and related treatments. For investors, they offer exposure to the healthcare industry, but their performance can be affected by clinical-trial results, regulatory decisions, patent expirations, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

LLY stock traded up $4.03 during midday trading on Friday, reaching $1,368.76. 1,431,981 shares of the company were exchanged, compared to its average volume of 2,952,261. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,453.00. The firm has a market capitalization of $1.29 trillion, a price-to-earnings ratio of 44.43, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The business has a 50-day moving average price of $1,211.30 and a two-hundred day moving average price of $1,099.50. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00.

Read Our Latest Research Report on LLY

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

PFE stock traded down $0.69 during trading hours on Friday, hitting $29.18. 23,668,330 shares of the stock were exchanged, compared to its average volume of 39,815,031. Pfizer has a 12 month low of $23.62 and a 12 month high of $31.44. The company has a current ratio of 1.42, a quick ratio of 0.96 and a debt-to-equity ratio of 0.67. The company has a 50-day simple moving average of $28.72 and a two-hundred day simple moving average of $26.88. The firm has a market capitalization of $166.34 billion, a P/E ratio of 41.75, a P/E/G ratio of 2.04 and a beta of 0.31.

Read Our Latest Research Report on PFE

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

JNJ stock traded up $1.90 during mid-day trading on Friday, hitting $274.22. The stock had a trading volume of 2,394,406 shares, compared to its average volume of 7,944,517. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $185.12 and a 52 week high of $282.02. The firm has a market capitalization of $660.14 billion, a P/E ratio of 41.54, a P/E/G ratio of 2.73 and a beta of 0.22. The firm has a fifty day simple moving average of $265.71 and a 200 day simple moving average of $248.01.

Read Our Latest Research Report on JNJ

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV stock traded up $2.33 during midday trading on Friday, reaching $290.57. 1,516,388 shares of the stock were exchanged, compared to its average volume of 6,331,854. The company has a fifty day moving average price of $271.31 and a 200 day moving average price of $238.65. The stock has a market capitalization of $513.61 billion, a PE ratio of 50.03, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie has a 52 week low of $190.75 and a 52 week high of $302.93.

Read Our Latest Research Report on ABBV

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

NYSE:MRK traded down $0.17 during trading hours on Friday, hitting $146.76. 2,662,411 shares of the company were exchanged, compared to its average volume of 10,627,387. Merck & Co., Inc. has a one year low of $85.24 and a one year high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $362.09 billion, a price-to-earnings ratio of 151.40, a price-to-earnings-growth ratio of 6.83 and a beta of 0.13. The company has a fifty day simple moving average of $146.45 and a 200 day simple moving average of $127.45.

Read Our Latest Research Report on MRK

Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.

NASDAQ RYTM traded up $4.88 during mid-day trading on Friday, reaching $109.91. 3,291,442 shares of the stock were exchanged, compared to its average volume of 841,911. Rhythm Pharmaceuticals has a one year low of $74.50 and a one year high of $122.20. The stock has a 50 day simple moving average of $96.16 and a 200-day simple moving average of $97.20. The stock has a market cap of $7.62 billion, a P/E ratio of -37.90 and a beta of 2.17.

Read Our Latest Research Report on RYTM

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

REGN traded up $2.44 during midday trading on Friday, hitting $905.35. The company had a trading volume of 361,212 shares, compared to its average volume of 831,349. Regeneron Pharmaceuticals has a 52 week low of $591.52 and a 52 week high of $991.73. The company has a market capitalization of $93.21 billion, a price-to-earnings ratio of 19.99, a PEG ratio of 1.38 and a beta of 0.10. The stock's 50 day moving average price is $802.45 and its 200 day moving average price is $741.95. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06.

Read Our Latest Research Report on REGN

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.